BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 30268765)

  • 1. Potential Novel Therapy Targets in Neuroendocrine Carcinomas of the Breast.
    Vranic S; Palazzo J; Sanati S; Florento E; Contreras E; Xiu J; Swensen J; Gatalica Z
    Clin Breast Cancer; 2019 Apr; 19(2):131-136. PubMed ID: 30268765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Profiling Reveals Limited Targetable Biomarkers in Neuroendocrine Carcinoma of the Cervix.
    Cimic A; Vranic S; Arguello D; Contreras E; Gatalica Z; Swensen J
    Appl Immunohistochem Mol Morphol; 2021 Apr; 29(4):299-304. PubMed ID: 33208671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Profiling of the Metaplastic Spindle Cell Carcinoma of the Breast Reveals Potentially Targetable Biomarkers.
    Vranic S; Stafford P; Palazzo J; Skenderi F; Swensen J; Xiu J; Spetzler D; Gatalica Z
    Clin Breast Cancer; 2020 Aug; 20(4):326-331.e1. PubMed ID: 32197944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive genetic features of gastric mixed adenoneuroendocrine carcinomas and pure neuroendocrine carcinomas.
    Koh J; Nam SK; Kwak Y; Kim G; Kim KK; Lee BC; Ahn SH; Park DJ; Kim HH; Park KU; Kim WH; Lee HS
    J Pathol; 2021 Jan; 253(1):94-105. PubMed ID: 32985687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic alterations of GI-NECs involving three main signaling pathways.
    Dai Q; Zhang J; Long W; Haybaeck J; Yang Z
    Cancer Med; 2023 Apr; 12(7):8238-8250. PubMed ID: 36653904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Characterization of Neuroendocrine Carcinomas of the Endometrium: Representation in All 4 TCGA Groups.
    Howitt BE; Dong F; Vivero M; Shah V; Lindeman N; Schoolmeester JK; Baltay M; MacConaill L; Sholl LM; Nucci MR; McCluggage WG
    Am J Surg Pathol; 2020 Nov; 44(11):1541-1548. PubMed ID: 32773531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic and Immunohistochemical Studies Investigating the Histogenesis of Neuroendocrine and Carcinomatous Components of Combined Neuroendocrine Carcinoma.
    Iijima M; Yokobori T; Mogi A; Shimizu K; Yajima T; Kosaka T; Ohtaki Y; Obayashi K; Nakazawa S; Gombodorj N; Tsukagoshi M; Shirabe K; Kuwano H
    Ann Surg Oncol; 2019 Jun; 26(6):1744-1750. PubMed ID: 30924018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microsatellite unstable gastrointestinal neuroendocrine carcinomas: a new clinicopathologic entity.
    Sahnane N; Furlan D; Monti M; Romualdi C; Vanoli A; Vicari E; Solcia E; Capella C; Sessa F; La Rosa S
    Endocr Relat Cancer; 2015 Feb; 22(1):35-45. PubMed ID: 25465415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of PD-1 and PD-L1 in poorly differentiated neuroendocrine carcinomas of the digestive system: a potential target for anti-PD-1/PD-L1 therapy.
    Roberts JA; Gonzalez RS; Das S; Berlin J; Shi C
    Hum Pathol; 2017 Dec; 70():49-54. PubMed ID: 29037958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are we ready to use TMB in breast cancer clinical practice?
    Ravaioli S; Limarzi F; Tumedei MM; Palleschi M; Maltoni R; Bravaccini S
    Cancer Immunol Immunother; 2020 Oct; 69(10):1943-1945. PubMed ID: 32725361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
    Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
    World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New model for gastroenteropancreatic large-cell neuroendocrine carcinoma: establishment of two clinically relevant cell lines.
    Krieg A; Mersch S; Boeck I; Dizdar L; Weihe E; Hilal Z; Krausch M; Möhlendick B; Topp SA; Piekorz RP; Huckenbeck W; Stoecklein NH; Anlauf M; Knoefel WT
    PLoS One; 2014; 9(2):e88713. PubMed ID: 24551139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Neuroendocrine carcinoma of breast: a study of tumor morphology and subtyping].
    Gao LX; Liu G; Li L; Lin HY; Jin H; Cheng J; Jin ML; Ding HY
    Zhonghua Bing Li Xue Za Zhi; 2011 Sep; 40(9):604-9. PubMed ID: 22177244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy.
    Gatalica Z; Xiu J; Swensen J; Vranic S
    Eur J Cancer; 2018 May; 94():179-186. PubMed ID: 29571084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olfactory receptor 51E1 protein as a potential novel tissue biomarker for small intestine neuroendocrine carcinomas.
    Cui T; Tsolakis AV; Li SC; Cunningham JL; Lind T; Öberg K; Giandomenico V
    Eur J Endocrinol; 2013 Feb; 168(2):253-61. PubMed ID: 23184910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages: An Assessment of 245 Primary and 40 Metastatic Tumors.
    Dill EA; Gru AA; Atkins KA; Friedman LA; Moore ME; Bullock TN; Cross JV; Dillon PM; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):334-342. PubMed ID: 28195880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel mutations in neuroendocrine carcinoma of the breast: possible therapeutic targets.
    Ang D; Ballard M; Beadling C; Warrick A; Schilling A; O'Gara R; Pukay M; Neff TL; West RB; Corless CL; Troxell ML
    Appl Immunohistochem Mol Morphol; 2015 Feb; 23(2):97-103. PubMed ID: 25679062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer.
    Chamberlin MD; Bernhardt EB; Miller TW
    J Cell Biochem; 2016 Nov; 117(11):2454-63. PubMed ID: 27146558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF
    Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
    Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.